CDKN2A and Alzheimer disease: Further, the brain tissue of patients who suffered from early onset AD (ages 35–50) had significantly increased expression of p16INK4a in astrocytes, with a greater burden of increased p16INK4a expression in the prefrontal cortex, an area known to atrophy during AD progression [58,61].